Market-Moving News for June 11th
$CMND
$MOLN
$OSG
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 8/30/2022 | Outperform → Sector Perform | RBC Capital Mkts | ||
| 8/29/2022 | $30.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink | |
| 5/25/2022 | Underperform → Neutral | Credit Suisse | ||
| 4/27/2022 | Neutral → Underperform | Credit Suisse |
4 - OVERSEAS SHIPHOLDING GROUP INC (0000075208) (Issuer)
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform
SVB Leerink downgraded Molecular Partners AG from Outperform to Mkt Perform and set a new price target of $8.00 from $30.00 previously
Credit Suisse upgraded Molecular Partners AG from Underperform to Neutral
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD su
OSG seeks to improve gender diversity in the maritime industry through scholarships to women pursuing careers at sea Overseas Shipholding Group, Inc. ("OSG") continues their efforts to remove financial barriers for women entering the maritime industry with a scholarship pledge in the amount of $30,000. The scholarship funds will be used to support the Women Offshore Foundation's 2024 Summer Sea Term Scholarship Program that is designed to help women+ enrolled at a U.S. maritime academy with financial support while they pursue a career on the water. This scholarship pledge is in addition to the $30,000 OSG provided to the Women Offshore Foundation used for four scholarships for the 2023 su
Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND), (FSE: CWY) ("Clearmind" or "the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board ("SAB"). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem. Prof. Tam is
This partnership aims to source global manufacturers and distributors for Clearmind's groundbreaking MEAI-based alcohol substitute beverages, marking a significant step towards international expansion.
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index surging more than 650 points on Tuesday. The Dow traded up 1.63% to 40,865.59 while the NASDAQ fell 0.11% to 18,452.31. The S&P 500 also rose, gaining, 0.37% to 5,652.28. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks Delivering High-Dividend Yields Leading and Lagging SectorsIndustrials shares jumped by 2.3% on Tuesday. In trading on Tuesday, information technology shares fell by 0.8%. Top Headline Morgan Stanley (NYSE:MS) reported better-than-expected second-quarter results. Morgan Stanley reported second-quarter EPS of $1.82, up from $1.24 a yea
Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results. Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from Benzinga Pro. Charles Schwab shares dipped 7.5% to $69.42 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results. Silo Pharma, Inc. (NASDAQ:SILO) shares climbed 95.4% to $2.12 after the company obtained an exclusive global l
4 - OVERSEAS SHIPHOLDING GROUP INC (0000075208) (Issuer)
4 - OVERSEAS SHIPHOLDING GROUP INC (0000075208) (Issuer)
4 - OVERSEAS SHIPHOLDING GROUP INC (0000075208) (Issuer)
Overseas Shipholding Group, Inc. (NYSE:OSG) (the "Company" or "OSG"), a leading provider of liquid bulk transportation services in the energy industry for crude oil and petroleum products in the U.S. Flag markets, today reported results for the first quarter of 2024. Net income for the first quarter of 2024 was $14.6 million, or $0.19 per diluted share, compared to net income of $12.1 million, or $0.14 per diluted share, for the first quarter of 2023. Adjusted EBITDA(A), a non-GAAP measure, for the first quarter of 2024 was $43.9 million, an increase of $3.0 million, or 7.3%, from the first quarter of 2023. Shipping revenues for the first quarter of 2024 were $117.5 million, an inc
Overseas Shipholding Group, Inc. (NYSE:OSG) (the "Company" or "OSG") announced today that it plans to release its first quarter results of fiscal year 2024 before the market opens on Friday, May 10, 2024. The Company will host a conference call and webcast to discuss its first quarter of fiscal year 2024 results at 9:30 a.m. ET on Friday, May 10, 2024. Event: OSG's Q1 2024 Earnings Release Conference Call When: Friday, May 10, 2024 at 9:30 a.m. ET Dial-In: (844) 850-0546 (US) or (412) 317-5203 (International) Participants have an option of calling in to listen or watching a live audio webcast and slide presentation available at the Investors section of the Company's website located at
Overseas Shipholding Group, Inc. (NYSE:OSG) (the "Company" or "OSG") announced today that its Board of Directors has declared a cash dividend of $0.06 per share on its Class A Common Stock. The dividend will be paid on April 11, 2024 to stockholders of record at the close of business on March 28, 2024. Sam Norton, OSG's President and CEO, commenting on the dividend declaration, stated, "After carefully considering the Company's capital position, I am pleased that our Board has declared another dividend on the heels of our earnings release, which highlighted our Company's strong financial condition. The dividend aligns with our commitment to return value to our shareholders while still mai
SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G - OVERSEAS SHIPHOLDING GROUP INC (0000075208) (Subject)
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317's ability to activate CD40 in a variety of tumor types further evidenced by comprehensive clinical biomarker analyses ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the presentation of data pertaining to two programs, including preclinical proof-of-concept for a novel T cell
Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of data from its MP0533 and MP0621 programs at the upcoming Annual Meeting of the American Society of
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025 RDT strategic agreement with Orano Med revised and strengthened: both companies to co-develop four 212Pb-based RDT candidates, including MP0712 MP0533 phase 1 dose escalation study continues; update to be presented at the American Society for Hematology Annual Meeting (ASH); protocol being amended to improve treatment exposure CD3 Switch-DARPin proof-of-mechanism to be presented at the Society for the Immunotherapy of Cancer Annual Meeting (SITC); update on Switch-DARPin MP06